SERPINC1 (Antithrombin III / ATIII) Drug Discovery Landscape & Assay Solutions
- By admin
- 13 Aug 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for Anticoagulant, Rare Disease, and Hemophilia Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SERPINC1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SERPINC1 (ATIII) Recombinant Protein & Deficiency Mutants High purity (>95%), Endotoxin <1 EU/µg. Sequence verified. HEK293 expressed for native glycosylation. Theoretical MW confirmed. |
View SERPINC1 Products |
| Gene Delivery | SERPINC1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View SERPINC1 Products |
| Benchmark Ab | Anti-SERPINC1 (ATIII) Antibody Recombinant positive control for PK/PD and capture assays. |
View SERPINC1 Products |
| Validator | SERPINC1 siRNA Set For knockdown and specificity verification. |
View SERPINC1 Products |
| Related Target: THBD | Thrombomodulin (THBD) Endothelial cofactor in the Protein C anticoagulant pathway; complementary thrombosis target. |
View THBD Products |
| Related Target: SERPIND1 | Heparin Cofactor II (SERPIND1) Parallel serpin inhibitor of thrombin; essential for selectivity and counter-screening panels. |
View SERPIND1 Products |
| Related Target: F2 | Prothrombin / Thrombin (F2) Primary protease target of ATIII; critical for activity and inhibition assays. |
View F2 Products |
| Related Target: F10 | Factor X (F10) Key coagulation factor regulated by SERPINC1; essential for coagulation cascade assays. |
View F10 Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heparin-dependent conformational activation (requires native glycosylation) | HEK293 expressed full-length protein with native glycosylation; >95% purity; endotoxin <1 EU/µg |
| Congenital deficiency mutant characterization (requires variant panel) | Sequence-verified mutant proteins; theoretical MW confirmed; custom deficiency variants available by rational design |
| Cross-species PK/PD and toxicology (cyno/mouse) | Human/Mouse/Cyno ortholog proteins available with >95% purity |
| Serpin off-target polymerization / latency screening | High-conformational-homogeneity prep; latent and polymeric forms strictly controlled during purification |
| siRNA knockdown validation and specificity check | Validated siRNA sets included for robust knockdown and RNAi benchmarking |
| Lack of standardization across batches | Sequence verified, endotoxin controlled (<1 EU/µg) batches ensure reproducibility |
Key Mutations and Variants
The following clinically relevant mutations in SERPINC1 are documented (UniProt P01008):
- AT3D type I mutation (VAR_027450): Associated with antithrombin deficiency type I, confirmed by clinical evidence.
- AT3D type I mutation (VAR_012748): This variant does not undergo post-translational glycosylation; dbSNP: rs3879.
- Dublin mutation (VAR_007032): dbSNP: rs2227624; a variant linked to altered antithrombin activity. TarMart offers custom mutant protein panels for functional studies of these and other deficiency-associated variants.
Global Clinical Landscape & Future Outlook
The race for SERPINC1 therapeutics is intensifying. Major players are shifting focus from traditional plasma-derived replacement to recombinant protein, gene therapy, and RNA interference (RNAi) modalities. For hereditary antithrombin deficiency, recombinant ATIII (e.g., ATryn) remains a standard. Meanwhile, RNAi therapies (e.g., Sanofi/Alnylam's Fitusiran) are advancing for hemophilia A and B, targeting SERPINC1 to rebalance coagulation. Next-wave R&D includes engineered superactive variants, liver-directed gene delivery, and highly specific subcutaneous delivery mechanisms to minimize off-target effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Replacement | LFB, Grifols, Kedrion, rEVO Biologics | Hereditary ATIII Deficiency, DIC, Sepsis | Activity & Heparin Cofactor Assay (Need native-folded, glycosylated antigen) |
| Gene Therapy | Academic / Emerging Biotech | Congenital Deficiency | Stable Expression Cell Lines (Need lentiviral ORF delivery) |
| Engineered Serpin Variants | Emerging biotech / Academia | Thrombosis, Heparin-Resistant States | Mutant vs WT Selectivity (Need sequence-verified mutant panel) |
| siRNA / RNAi | Sanofi (Alnylam) | Hemophilia A and B | Knockdown Assay (Need Validated siRNA and High-purity Proteins) |
| Small Molecules | Various Academic | Thrombosis | Selectivity Assay (Need Homolog Panel Proteins) |
| Diagnostic / Companion | Instrumentation vendors | Heparin Monitoring, Deficiency Screening | Calibrator Proteins (Need high-purity, endotoxin-controlled standards) |
Live SERPINC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: